Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10444336 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL9214648 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL9737302 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL10501805 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL6380675 | 0.98 | SIGMAR1 (0.43) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL10444597 | 0.95 | SIGMAR1 (0.42) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL7055348 | 0.95 | SIGMAR1 (0.42) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL7054446 | 0.95 | SIGMAR1 (0.46) | SIGMAR1CYP1A2NAAAEPHX1EPHX2 | |
| SCHEMBL921655 | 0.93 | SIGMAR1 (0.39) | SIGMAR1CYP1A2NAAAMEN1KMT2A | |
| SCHEMBL920855 | 0.91 | CYP1A2 (0.41) | SIGMAR1CYP1A2NAAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | SIGMAR1 119/4885CYP1A2 2162/4885NAAA 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.